Summit Therapeutics

Apple's 'It’s Glowtime' event to unveil iPhone 16 with AI capabilities, Summit Therapeutics shares soar on positive lung cancer drug trial results, Palantir jumps on S&P 500 inclusion news, Boeing stock surges after union deal, and futures point to higher open for major indexes.

Akeso's PD-1/VEGF bispecific antibody ivonescimab showed significant results in a Phase II study for perioperative treatment of resectable NSCLC, with higher pCR and MPR rates when combined with chemotherapy. Ivonescimab, a global first-in-class immunotherapy drug, is being developed for multiple cancer indications and has met primary endpoints in Phase III studies, with several ongoing and planned clinical trials.

Ivonescimab, a novel bispecific antibody, demonstrated superior progression-free survival (PFS) over pembrolizumab in a Phase III trial for first-line PD-L1 high, advanced NSCLC, with a median PFS of 11.14 months vs. 5.82 months. The trial showed comparable safety profiles, with manageable treatment-related adverse events. Summit Therapeutics plans to initiate HARMONi-7, another Phase III trial, in early 2025.

Summit Therapeutics' experimental drug ivonescimab reduced lung cancer progression risk by 49% compared to Merck's Keytruda in a Phase 3 trial, with a median progression-free survival of 11 months versus 6 months for Keytruda. Ivonescimab, discovered by Akeso, targets PD-1 and VEGF, showing potential to become a new standard treatment, though further global trials are needed to confirm its superiority over Keytruda plus chemotherapy.

Akeso's PD-1/VEGF bispecific antibody ivonescimab showed significant Phase II results for perioperative treatment of resectable NSCLC at WCLC 2024. Ivonescimab, either as monotherapy or combined with chemotherapy, demonstrated high rates of pathological complete response (pCR) and major pathological response (MPR). Safety profile was manageable, with no TRAEs causing surgery cancellations or delays.

Summit Therapeutics' experimental therapy, ivonescimab, outperformed Merck's Keytruda in a late-stage lung cancer trial, reducing tumor progression risk by 49%.